Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dr Reddys Laboratories (RDY) EBT (2016 - 2025)

Historic EBT for Dr Reddys Laboratories (RDY) over the last 17 years, with Q4 2025 value amounting to $173.3 million.

  • Dr Reddys Laboratories' EBT fell 2194.91% to $173.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $864.0 million, marking a year-over-year decrease of 208.66%. This contributed to the annual value of $900.0 million for FY2025, which is 440.84% up from last year.
  • Dr Reddys Laboratories' EBT amounted to $173.3 million in Q4 2025, which was down 2194.91% from $231.6 million recorded in Q1 2025.
  • In the past 5 years, Dr Reddys Laboratories' EBT registered a high of $237.2 million during Q3 2024, and its lowest value of $199.0 during Q3 2022.
  • In the last 5 years, Dr Reddys Laboratories' EBT had a median value of $195.0 million in 2022 and averaged $172.7 million.
  • Per our database at Business Quant, Dr Reddys Laboratories' EBT plummeted by 9999.98% in 2022 and then soared by 11631333458.01% in 2023.
  • Over the past 5 years, Dr Reddys Laboratories' EBT (Quarter) stood at $31.0 million in 2021, then surged by 422.58% to $162.0 million in 2022, then skyrocketed by 38.07% to $223.7 million in 2023, then dropped by 0.76% to $222.0 million in 2024, then dropped by 21.95% to $173.3 million in 2025.
  • Its EBT stands at $173.3 million for Q4 2025, versus $231.6 million for Q1 2025 and $222.0 million for Q4 2024.